Vizex Investments Ltd
financial consultations

Last news

Long term recommendation - Immune Pharmaceuticals (NASDAQ.IMNP)

Feb 04, 2018 35
Febryary 4th. We are starting coverage…

Transenterix completely sold the rights on the Surgibot

Dec 18, 2017 36
December 18th 2017. Transenterix…

Transenterix announces Q3 2017 results

November 9th.  Transenterix announced financial results and business update for Q3 2017

Key highlights

-The Senhahce robot has been approved by FDA for commercial sales in the U.S

-1 robot sold in Taiwan in Q3 2017

-Commercial infrastructure built in the U.S. - 17 sales representatives in place.

-1 sales pending (pre order issued) in EU - to be booked in Q4

-At least 1 sale expected in the U.S. in Q4

-$100 M cash in bank - enough to keep the company running well beyond 2018

Вайзекс Инвестментс ООД © 2015 | Всички права запазени